Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

This study has been completed.

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00237172

Purpose

This is a extension study of CSTI571B1201 study

Condition	Intervention	Phase
Gastrointestinal Stromal Tumors	Drug: Imatinib Mesylate	Phase II

MedlinePlus related topics: Cancer

Drug Information available for: Imatinib Imatinib mesylate

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Novartis:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	72
Study Start Date:	September 2002

Eligibility

Criteria

Inclusion Criteria:

- Patients who completed the CSTI571B1201 study

Exclusion Criteria:

Other protocol-defined inclusion / exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00237172

Sponsors and Collaborators

Novartis

Investigators

Study Chair:

Novartis

More Information

Study ID Numbers:	CSTI571B1202
Study First Received:	October 9, 2005
Last Updated:	May 26, 2006
ClinicalTrials.gov Identifier:	NCT00237172
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Novartis:

GIST
Imatinib
STI571
Gastrointestinal Stromal Tumors

Study placed in the following topic categories:

Imatinib
Digestive System Diseases
Digestive System Neoplasms

Gastrointestinal Diseases
Gastrointestinal Neoplasms
Gastrointestinal Stromal Tumors

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

Therapeutic Uses
Enzyme Inhibitors
Protein Kinase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009